title: Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension.
abstract: Recent evidence shows that leptin may contribute to elevated blood pressure (BP) and interact with the renin-angiotensin-aldosterone and cellular immune systems. Altered T-cell activities and changes in T-cell subset ratios have also been reported in hypertension. However, little is known about the effects of AT1-receptor antagonism on T-cell activities and plasma leptin concentrations in primary hypertension. We have, therefore, investigated the relationship between leptin and T-cell activities and the effect of an AT1-receptor antagonist, losartan, in primary hypertension. Twenty recently-diagnosed and untreated young adults (11 males and 9 females, age; 39.9+/-7.6 years, range 23-49 years, BMI; 27.6+/-3.7kg/m2) and 20 normotensive healthy, age-, sex- and BMI-matched controls were studied. The [3H]-thymidine uptakes of cultured lymphocytes were determined, both spontaneously and after stimulation with phytohaemagglutinin. The tests were performed before and after three months of treatment with losartan. The results indicate that the blastogenic responses of T-cells to phytohaemagglutinin are significantly higher in the patient group compared with controls (p=0.02). After normalisation of BP, T-cell responses were significantly reduced and were lower than in the controls (p=0.01). Pretreatment plasma leptin levels were significantly higher in hypertensives than in controls (p=0.01). However, losartan treatment had no significant effect on leptin concentrations; moreover, no correlation between leptin levels and T-cell activity was found. Our data show that plasma leptin levels and T-cell activity are markedly enhanced in untreated essential hypertension and that the alteration of T-cell activity is not related to plasma leptin levels. Antihypertensive treatment with losartan decreases T-cell activities but does not influence plasma leptin levels. We conclude that leptin levels are not affected by AT1-receptor blockade and are not related to T-cell activity.
authors.affiliation: Department of Internal Medicine, Gulhane School of Medicine, Etlik-Ankara, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Sonmez
authors.forename: U
authors.initials: U
authors.lastname: Kisa
authors.forename: G
authors.initials: G
authors.lastname: Uckaya
authors.forename: T
authors.initials: T
authors.lastname: Eyileten
authors.forename: B
authors.initials: B
authors.lastname: Comert
authors.forename: B
authors.initials: B
authors.lastname: Koc
authors.forename: F
authors.initials: F
authors.lastname: Kocabalkan
authors.forename: M
authors.initials: M
authors.lastname: Ozata
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D020738:Leptin / Q000097:blood*; D019808:Losartan / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000187:drug effects*
chemical_list: D000959:Antihypertensive Agents; D020738:Leptin; D019808:Losartan